BioSpace News Archive

OraSure Technologies, Inc. announced it has commenced an underwritten public offering of 8,000,000 shares of its common stock.

A federal judge has ordered two individuals doing business as Sundial Herbal Products to stop distributing unapproved new drugs and misbranded drugs until they comply with federal law.

Arena Pharmaceuticals, Inc. announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a price to the public of $50.00 per share, including 825,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

Varian announced two executive appointments. Michael Hutchinson has joined the company as Senior Vice President, Chief Legal Officer following the previously communicated retirement plans of John Kuo.

Kaleido Biosciences, Inc., a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, announced that it intends to sell, subject to market and other conditions, $30 million of shares of its common stock in an underwritten public offering.

Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced that members of its management team will participate in presentations and meetings at the Jefferies Virtual Healthcare Conference with institutional investors taking place June 2-4, 2020.

The COVID-19 pandemic has resulted in significant shifts in the supply and demand of certain drugs. While supply levels may be stabilizing, supply pressures continue for certain drugs.

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced financial and operating results for the fourth quarter and full year ended December 31, 2019.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced that the company will hold a webcast on Friday, June 5, 2020 at 8.30 a.m. to present additional results and analyses from its Phase 3 trial in negative symptoms.

Shanghai Henlius Biotech, Inc. (2696.HK) and Accord Healthcare Limited (Accord) jointly announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for biosimilar HLX02